Poll Results Highlight Gynecologic Oncology Abstracts to Watch Ahead of ESMO 2025

The 2025 ESMO Congress is now less than 1 week away, and to help you continue to gear up for this year’s meeting, OncLive® conducted polls on both X and LinkedIn to determine which gynecologic oncology cancer abstracts and disease areas oncology specialists were most eager to learn about in Berlin.

See the results of our 2 polls below, plus more on the abstracts to watch during the meeting.

Poll results

Poll 1 – Which gynecologic cancer abstract are you most anticipating at ESMO 2025?

• LBA40: WES-derived Aneuploidy score (W-AS) identifies MMRd patients with reduced benefit from immunotherapy in endometrial cancer. Multi-omic analysis of the phase III AtTEnd/ENGOT-EN7 trial
• LBA44: Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: final overall survival from DUO-O/ENGOT-ov46/GOG-3025
• LBA45: ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): relacorilant + nab-paclitaxel in the subgroup of patients with platinum-resistant ovarian cancer (PROC) previously exposed to a PARP inhibitor
• LBA38: Phase 3 study of camrelizumab plus famitinib versus platinum-based chemotherapy as first-line therapy for recurrent or metastatic cervical cancer

Among 45 respondents on LinkedIn, 69% voted for the phase 3 ROSLLA trial (NCT05257408) evaluating relacorilant in combination with nab-paclitaxel (Abraxane) compared with nab-paclitaxel alone in patients with platinum-resistant ovarian cancer. All 3 respondents on X also concurred that the ROSELLA study was the top abstract to watch. On LinkedIn, additional votes were recorded for the phase 3 DUO-O trial (NCT03737643) of durvalumab plus chemotherapy and bevacizumab (Avastin) in advanced ovarian cancer (18%), the phase 3 AtTEnd study (NCT03603184) in endometrial cancer (9%), and the phase 3 study of camrelizumab plus famitinib (4%).

Poll 2 – Which gynecologic cancer subtype are you more interested in learning more about during ESMO 2025?

• Ovarian Cancer
• Endometrial Cancer
• Cervical Cancer

On both LinkedIn (n = 66) and X (n = 6), respondents agreed that ovarian cancer was the top gynecologic oncology subtype to watch during ESMO 2025, with ovarian cancer receiving 67% and 50% of the respective votes. This was followed by endometrial cancer (26%; 33.3%) and cervical cancer (8%; 16.7%)

Abstract Information

LBA40

The phase 3 AtTEnd study was randomized trial that evaluated the combination of atezolizumab (Tecentriq) plus chemotherapy vs placebo plus chemotherapy alone in patients with advanced or recurrent endometrial cancer. Previously reported data from the study demonstrated that the combination of atezolizumab and chemotherapy improved progression-free survival (PFS), particularly among patients with mismatch repair–deficient endometrial cancer.1

The study also integrated whole-exome sequencing (WES) to evaluate the WES-derived aneuploidy score (W-AS)as a predictive biomarker in the dMMR population, which will be presented during ESMO 2025

LBA44

DUO-O was a double-blind, randomized trial that assessed durvalumab plus paclitaxel or carboplatin and bevacizumab, followed by durvalumab, bevacizumab, and olaparib (Lynparza) maintenance, in patients with newly diagnosed, non–BRCA-mutated advanced ovarian cancer. Investigators will present the final overall survival analysis during ESMO 2025 after the study previously demonstrated a PFS advantage in the experimental arm.2

LBA45

This randomized phase 3 study investigated relacorilant plus nab-paclitaxel versus nab-paclitaxel alone in platinum-resistant ovarian cancer. After a PFS improvement was reported with a prior analysis, the subgroup analysis being presented during ESMO 2025 will focus on a subgroup analysis featuring patients who were previously treated with a PARP inhibitor before enrolling on the study.3

LBA38

A randomized, open-label, controlled, multicenter phase 3 trial (NCT04906993) conducted in China evaluated camrelizumab plus famitinib vs platinum-based chemotherapy in the treatment of patients with metastatic/recurrent endometrial cancer.4

References

1. Colombo N, Biagioli E, Harano K, et al. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024;25(9):1135-1146. doi:10.1016/S1470-2045(24)00334-6
2. Lynparza and Imfinzi combination improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without tumour BRCA mutations in DUO-O Phase III trial. News release. AstraZeneca. April 5, 2023. Accessed October 9, 2025. https://www.astrazeneca.com/media-centre/press-releases/2023/lynparza-imfinzi-met-endpoint-in-ovarian-cancer.html#modal-historic-confirmation
3. L, Gilbert L, et al. ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72). J Clin Oncol. 2025;43(suppl 17):LBA5507. doi:10.1200/JCO.2025.43.17_suppl.LBA5507
4. Camrelizumab combined with famitinib malate for treatment of recurrent/​metastatic cervical cancer. ClinicalTrials.gov. Updated September 9, 2025. Accessed October 9, 2025. https://www.clinicaltrials.gov/study/NCT04906993